Do quality of life assessments make a difference in the evaluation of cancer treatments?

Controlled Clinical Trials

Volumn 18, Issue 4, 1997, Pages 311-317

  Moinpour, Carol M ^a  

^a SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

Author keywords

Measurement error; Missing data; Palliation; Quality of life

Indexed keywords

CISPLATIN; HYDRAZINE SULFATE; PLACEBO; VINBLASTINE;

ADVANCED CANCER; ANALYTICAL ERROR; CANCER; CANCER THERAPY; CLINICAL TRIAL; DATA ANALYSIS; HUMAN; MEASUREMENT; METHODOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; SHORT SURVEY;

EID: 0030804942     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(97)00054-8     Document Type: Article

References (19)

1. Korn EL. Assessing quality of life in comparative cancer clinical trials: does it make a difference? Controlled Clin Trials 1997;18:275-276.
2. Moinpour CM. Costs of quality-of-life research in Southwest Oncology Group trials. J Natl Cancer Inst Mon 1996;20:11-16.
3. Herndon JE II, Fleishman S, Kosty MP, Green MR. A longitudinal study of quality of life in advanced non-small cell lung cancer: CALGB 8931. Controlled Clin Trials 1997;18:286-300.
4. Scott CB. Quality-adjusted survival analysis of malignant glioma patients. Controlled Clin Trials 1997;18:277-285.
5. Moore MJ, Osoba D, Murphy K, et al. Use of palliative end points to evaluate the effects of Mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 1994;12:689-694.
6. Aaronson NK, Ahmedzai S, Bergman B, et al. for the European Organization for Research and Treatment of Cancer Study Group on Quality of Life. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
7. Aaronson NK, Ahmedzai S, Bullinger M, et al. for the EORTC Study Group on Quality of Life. The EORTC Core quality-of-life questionnaire: interim results of an international field study. In: Osoba D, ed. Effect of Cancer on Quality of Life. Boca Raton, FL: CRC Press, Inc.; 1991:185-203.
8. Gelber RD, Gelman RS, Goldhirsch A. A quality-of-life oriented endpoint for comparing therapies. Biometrics 1989;45:781-795.
9. Kaplan RM. Quality of life assessment for cost/utility studies in cancer. Cancer Trt Rev 1993;19:85-96.
10. Hopwood P, Stephens RJ, Machin D for the MRC Lung Cancer Working Party. Approaches to the analysis of quality of life data: experiences gained from a Medical Research Council Lung Cancer Working Party palliative chemotherapy trial. Qual Life Res 1994;3:339-392.
11. Machin D. Assessing quality of life in comparative cancer clinical trials: does it make a difference? Controlled Clin Trials 1997;18:301-305.
12. Nayfield SG, Ganz PA, Moinpour CM, et al. Report from a National Cancer Institute (USA) workshop on quality of life assessment in cancer clinical trials. Qual Life Res 1992;1:203-210.
13. Schag CC, Heinrich RL, Ganz PA. Karnofsky Performance Status revisited: reliability, validity and guidelines. J Clin Oncol 1984;2:187-193.
14. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
15. Niezgoda HE, Pater JL. A validation study of the domains of the core EORTC Quality of Life Questionnaire. Qual Life Res 1993;2:319-325.
16. Ringda GI, Ringdal K. Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses. Qual Life Res 1993;2:129-140.
17. Nunnally JC. Psychometric theory 2nd ed. New York: McGraw Hill;1978:210,241-246.
18. Leon AC, Marzuk PM, Portera L. More reliable outcome measures can reduce sample size requirements. Arch Gen Psychiatry 1995;52:867-871.
19. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297-334.